Fertility and IVF: Clinics, Costs, Egg Freezing and the Law — 2026-10-23
Recent legislative efforts in the U.S. threaten to impose new restrictions on IVF clinics, while South Korea faces a surge in non-insured fertility treatment costs despite expanded government subsidies. Meanwhile, a growing trend of "fertility tourism" sees patients traveling to Mexico, Spain, and Korea for more accessible care, and a new U.S. market report highlights AI's role in driving a 4.98% CAGR in the ART sector.
Fertility and IVF: Clinics, Costs, Egg Freezing and the Law — 2026-10-23
Top developments
U.S. Legislative Threats to IVF Access
A newly published legal analysis by Reed Smith warns of active state legislative threats to assisted reproductive technology (ART). Specifically, a bill in one state (HB 2948) that would have taken effect on November 1, 2026, was defeated but may resurface in the next session. This underscores the need for healthcare executives and physicians to monitor regulatory risks across multiple states, as legal definitions of embryos and access restrictions continue to evolve.
South Korea’s Non-Insured Cost Surge
In South Korea, government expansion of fertility support has paradoxically led to significant price hikes in non-insured (non-reimbursed) treatment items. Data released during National Assembly audits revealed that prices for certain non-insured procedures rose by over 120,000 KRW, with some items like sperm retrieval seeing increases of up to 52.8%. This trend has caused financial strain for couples who rely on a mix of subsidies and out-of-pocket payments.
Rise of Fertility Tourism
Condé Nast Traveler reports a rising wave of "fertility tourism," with patients increasingly traveling to Mexico, Spain, and Korea for egg freezing and IVF. The report highlights that these destinations often offer more accessible and affordable treatment options compared to the U.S., where costs and legal uncertainties can be prohibitive. This shift is impacting local clinic chains in destination countries, which are adapting to serve international patients.
AI-Driven ART Market Growth
A new market report on the U.S. Assisted Reproductive Technology (ART) market projects a 4.98% CAGR from 2026 to 2034. The growth is fueled by AI-enabled IVF technologies and fertility preservation services. The report suggests that clinics can boost ROI through multi-cycle packages, ancillary PGT (preimplantation genetic testing) revenue, and AI-driven clinic operations, signaling a tech-heavy future for fertility care.
Japan’s Petition to Lift IVF Cycle Limits
In Japan, a signature campaign has launched to demand the removal of the "cycle limit" for insured infertility treatments. Currently, insured coverage for IVF/ICSI is limited to six cycles for women under 40 (and three for those aged 40-42). Advocates argue that these restrictions force patients into expensive out-of-pocket treatments or cause emotional distress by cutting off care prematurely.
Local view
South Korea: Local media outlets like Hankyung and Gukje News are criticizing the government's fertility support policies, noting that while subsidies have increased, the lack of price controls on non-insured items has allowed clinics to raise costs. Hankyung specifically highlighted that pregnant women’s ultrasound costs rose by 15.2% in the year subsidies were expanded, suggesting a pattern of cost-shifting to patients.
Japan: Sankei Shimbun is covering the grassroots movement in Japan calling for the abolition of the "number of times limit" for insured IVF treatments. The petition argues that the current cap on insured cycles is outdated and disproportionately affects older patients and those with complex fertility issues.
Context & numbers
- U.S. ART Market Growth: The U.S. ART market is projected to grow at a 4.98% CAGR through 2034, driven by AI integration and fertility preservation.
- Korea Non-Insured Price Hikes: Following expanded subsidies in 2024, non-insured fertility procedure prices in South Korea rose significantly, with some items increasing by over 50%.
- Japan Insured Cycle Limits: Japan currently limits insured IVF/ICSI treatments to 6 cycles for women under 40 and 3 cycles for women aged 40-42.
On the radar
- U.S. State Legislation: Monitor upcoming legislative sessions in states where IVF restrictions were debated but not passed in 2026, as similar bills are expected to resurface.
- Korea Audit Results: Further details from the South Korean National Assembly audits on health insurance and fertility costs are expected to emerge, potentially leading to new regulatory discussions on non-insured pricing.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
